University of Aberdeen logo

AURA - Aberdeen University Research Archive

 

Patients' Preferences for Cytoreductive Treatments in Newly Diagnosed Metastatic Prostate Cancer : The IP5-MATTER Study

Simple item page
dc.contributor.authorConnor, Martin J.
dc.contributor.authorGenie, Mesfin
dc.contributor.authorDudderidge, Tim
dc.contributor.authorWu, Hangjian
dc.contributor.authorSukumar, Johanna
dc.contributor.authorBeresford, Mark
dc.contributor.authorBianchini, Diletta
dc.contributor.authorGoh, Chee
dc.contributor.authorHoran, Gail
dc.contributor.authorInnominato, Pasquale
dc.contributor.authorKhoo, Vincent
dc.contributor.authorKlimowska-Nassar, Natalia
dc.contributor.authorMadaan, Sanjeev
dc.contributor.authorMangar, Stephen
dc.contributor.authorMcCracken, Stuart
dc.contributor.authorOstler, Peter
dc.contributor.authorPaisey, Sangeeta
dc.contributor.authorRobinson, Angus
dc.contributor.authorRai, Bhavan
dc.contributor.authorSarwar, Naveed
dc.contributor.authorSrihari, Narayanan
dc.contributor.authorJayaprakash, Kamal Thippu
dc.contributor.authorVarughese, Mohini
dc.contributor.authorWinkler, Mathias
dc.contributor.authorAhmed, Hashim U.
dc.contributor.authorWatson, Verity
dc.contributor.authorIP5-MATTER Trial Investigators
dc.contributor.institutionUniversity of Aberdeen.Health Economics Research Uniten
dc.date.accessioned2025-10-30T15:55:01Z
dc.date.issued2025-06
dc.descriptionWe would like to thank all the participants, study principal investigators, trial clinicians, research nurses, Imperial Clinical Trial Unit staff, NIHR Clinical Research Network (CRN) Portfolio, and other site staff who were responsible for set-up, recruitment, and delivery of the IP5-MATTER study. We are also grateful for the support of the trial management group and our patient representatives. We would also like to thank our trial funders the Wellcome Trust and University College London Hospitals (UCLH) Charity. Finally, we would like to thank Dr. Luis Loria Rebolledo for his advice on statistical modelling. IP5-MATTER Trial Investigators: Nicholas Temple (trial patient representative, Imperial College London); Ms. Natalia Klimowska-Nassar and Mr. Feargus Hosking-Jervis (Imperial College Clinical Trials Unit, Imperial College London); Dr. Alison Falconer and Dr. Michael Gonzalez (Charing Cross Hospital, Imperial College Healthcare NHS Trust); Professor Matin Sheriff (Medway Maritime Hospital); Ms. Deborah Kemp (Sunderland Royal Hospital); Professor Iqball Shergill (Betsi Cadwaladr University Health Board, Wrexham Maelor Hospital); Ms. Lesley Harden (The Royal Surrey County Hospital); Ms Nikki Carney (University Hospital Southampton), Dr. Saheel Mukhtar (East Surrey Hospital); Dr. Duncan Wheatly (The Royal Cornwall Hospital); Dr. Denise Sheehan and Mr. John McGrath (The Royal Devon and Exeter Hospital); Dr. Alison Reid (Kingston Hospital); Dr. Anna Bowzykal Al-Naeeb (Bedford Hospital); Dr. Susannah Brock (University Hospitals Dorset NHS Foundation Trust); Ms. Ling Lee (The Royal Bolton Hospital); Dr. Dakshinamoorthy Muthu Kumar (East Suffolk and North Essex NHS Foundation Trust); Dr. Sanjay Dixit (Grimsby Hospital, Diana Princess of Wales); and Dr. Milan Anjanappa (Luton and Dunstable Hospital). Additional information: N. Temple, our patient representative for the IP5-MATTER trial, died in 2023.en
dc.description.statusPeer revieweden
dc.format.extent11
dc.format.extent1332156
dc.identifier305653182
dc.identifiere5302d5e-b435-49fc-9b61-0e73475dd424
dc.identifier105008082558
dc.identifier38972831
dc.identifier.citationConnor, M J, Genie, M, Dudderidge, T, Wu, H, Sukumar, J, Beresford, M, Bianchini, D, Goh, C, Horan, G, Innominato, P, Khoo, V, Klimowska-Nassar, N, Madaan, S, Mangar, S, McCracken, S, Ostler, P, Paisey, S, Robinson, A, Rai, B, Sarwar, N, Srihari, N, Jayaprakash, K T, Varughese, M, Winkler, M, Ahmed, H U, Watson, V & IP5-MATTER Trial Investigators 2025, 'Patients' Preferences for Cytoreductive Treatments in Newly Diagnosed Metastatic Prostate Cancer : The IP5-MATTER Study', European Urology Oncology, vol. 8, no. 3, pp. 663-673. https://doi.org/10.1016/j.euo.2024.06.010en
dc.identifier.doi10.1016/j.euo.2024.06.010
dc.identifier.issn2588-9311
dc.identifier.urihttps://hdl.handle.net/2164/26336
dc.identifier.urlhttp://www.scopus.com/inward/record.url?scp=105008082558&partnerID=8YFLogxKen
dc.language.isoeng
dc.relation.ispartofEuropean Urology Oncologyen
dc.subjectSDG 3 - Good Health and Well-beingen
dc.subjectCryotherapyen
dc.subjectCytoreductiveen
dc.subjectDiscrete choice experimenten
dc.subjectMetastasis-directed therapyen
dc.subjectMetastatic prostate canceren
dc.subjectOligometastatic diseaseen
dc.subjectPatient preferenceen
dc.subjectRadical prostatectomyen
dc.subjectRadiotherapyen
dc.subjectStereotactic ablative body radiotherapyen
dc.subjectRC0254 Neoplasms. Tumors. Oncology (including Cancer)en
dc.subjectGeneral Medicineen
dc.subject.lccRC0254en
dc.titlePatients' Preferences for Cytoreductive Treatments in Newly Diagnosed Metastatic Prostate Cancer : The IP5-MATTER Studyen
dc.typeJournal articleen

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Connor_etal_EUO_Patients_Preferences_for_VOR.pdf
Size:
1.27 MB
Format:
Adobe Portable Document Format
Download

Collections

All research